US Patent

US9314447 — Reduced dose pharmaceutical compositions of fenofibrate

Method of Use · Assigned to Lupin Atlantis Holdings SA · Expires 2033-05-31 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a reduced dose oral pharmaceutical composition made from a mixture of nanoparticulate fenofibrate and micronized fenofibrate.

USPTO Abstract

The present invention provides a reduced dose oral pharmaceutical composition comprising mixture of nanoparticulate fenofibrate and micronized fenofibrate and one or more pharmaceutically acceptable excipients.

Drugs covered by this patent

Tricor (Micronized) (FENOFIBRATE) · Salix

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1447`	—	Tricor (Micronized)

Patent Metadata

Patent number: US9314447
Jurisdiction: US
Classification: Method of Use
Expires: 2033-05-31
Drug substance claim: No
Drug product claim: Yes
Assignee: Lupin Atlantis Holdings SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.